Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 245

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Complex karyotype is a stronger predictor than del(17p) for an inferior outcome in relapsed or refractory chronic lymphocytic leukemia patients treated with ibrutinib‐based regimens

Open access
Thompson, Philip A., O'Brien, Susan M., Wierda, William G., Ferrajoli, Alessandra, Stingo, Francesco, Smith, Susan C., Burger, Jan A., Estrov, Zeev, Jain, Nitin, Kantarjian, Hagop M., Keating, Michael J.·2015·Cancer

Abstract

BACKGROUND: Ibrutinib is active in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL). In patients treated with ibrutinib for R/R CLL, del(17p), identified by interphase fluorescence in situ hybridization (FISH), is associated with inferior progression‐free survival despite equivalent initial response rates. Del(17p) is frequently associated with a complex metaphase karyotype (CKT); the prognostic significance of CKT in ibrutinib‐treated patients has not been reported. METHODS: This study reviewed 88 patients treated for R/R CLL at The University of Texas MD Anderson Cancer Center with investigational ibrutinib‐based regimens from 2010 to 2013. Pretreatment FISH and lipopolysaccharide‐stimulated metaphase cytogenetic analysis were performed on bone marrow. RESULTS: An adequate pretreatment metaphase karyotype was available for 56 of the 88 patients. The karyotype was complex in 21 of the 56 cases; 17 of the 21 had del(17p) according to FISH. The overall response rate, including partial remission with persistent lymphocytosis, was 94%; 18% had complete responses. In a multivariate analysis (MVA), only CKT was significantly associated with event‐free survival (EFS; hazard ratio [HR], 6.6 [95% CI 1.7‐25.6]; P = .006). Fludarabine‐refractory CLL (HR, 6.9 [95% CI 1.8‐27.1], P = .005) and CKT (HR 5.9 [95% CI 1.6‐22.2], P = .008) were independently associated with inferior overall survival (OS) in MVA. Del(17p) by FISH was not significantly associated with EFS or OS in MVA. CONCLUSIONS: CKT is a powerful predictor of outcomes for ibrutinib‐treated patients with R/R CLL and may be a stronger predictor of biological behavior than del(17p) by FISH. Because of their relatively poor outcomes, patients with CKT are ideal candidates for studies of consolidative treatment strategies or novel treatment combinations. Cancer 2015 © 2015 American Cancer Society. Cancer 2015;121:3612–3621. © 2015 American Cancer Society.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/cncr.29566

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 245

Metadata

Authors
Thompson, P. A., O'Brien, S. M., Wierda, W. G., Ferrajoli, A., Stingo, F., Smith, S. C., Burger, J. A., Estrov, Z., Jain, N., Kantarjian, H. M., & Keating, M. J.
Venue
Cancer
Publisher
Wiley
Published
2015-07-20
Volume
121
Issue
20
Pages
3612-3621
ISSN
  • 0008-543X (ISSN-L)
  • 1097-0142
OpenAlex
W2140052555
Cited by
245
References
2
FWCI
19.40
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Complex karyotype is a stronger predictor than del(17p) for an inferior outcome in relapsed or refractory chronic lymphocytic leukemia patients treated with ibrutinib‐based regimens. https://app.cochat.ai/papers/10.1002/cncr.29566
The paper
Thompson, P. A., O'Brien, S. M., Wierda, W. G., Ferrajoli, A., Stingo, F., Smith, S. C., Burger, J. A., Estrov, Z., Jain, N., Kantarjian, H. M., & Keating, M. J. (2015). Complex karyotype is a stronger predictor than del(17p) for an inferior outcome in relapsed or refractory chronic lymphocytic leukemia patients treated with ibrutinib‐based regimens. Cancer. https://doi.org/10.1002/cncr.29566

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.